MicroRNA-203 Expression as a New Prognostic Marker of Pancreatic Adenocarcinoma

MicroRNA-203 Expression as a New Prognostic Marker of Pancreatic Adenocarcinoma
复制标题

DOI:
10.1245/s10434-010-1188-8
复制
发表时间:
2010-12-01
影响因子:
3.7
通讯作者:
Tanaka, Masao
Tanaka, Masao
中科院分区:
医学2区
文献类型:
--
作者:
Ikenaga, Naoki;Ohuchida, Kenoki;Tanaka, Masao

文献摘要

被引文献

相似文献

microRNA(miR)异常表达的检测有助于多种癌症的诊断和预后。为探讨miR-203表达与胰腺癌根治性切除术后患者预后的关系,收集113例胰腺癌组织、20例慢性胰腺炎组织和8例正常胰腺组织标本。我们研究了miR-203表达与临床病理参数和生存时间的关系,miR-203在胰腺癌中的表达高于慢性胰腺炎(P < 0.001)和正常胰腺(P = 0.001)。未观察到miR-203表达与胰腺癌临床病理因素之间的相关性。在单变量分析中,高miR-203组和具有最高miR-203过表达的病例亚组(20%)具有显著更短的生存时间(分别为P = 0.048和P = 0.024)。多因素分析显示,miR-203表达是无残留肿瘤患者预后不良的独立预测因子(相对危险度2.298,P = 0.027),miR-203表达是胰腺癌患者新的预后指标。
Detection of aberrant microRNA (miR) expression may contribute to diagnosis and prognosis of various cancers. The aim of this study is to evaluate the correlation between miR-203 expression and prognosis of patients with pancreatic adenocarcinoma after curative resection.A total of 113 formalin-fixed paraffin-embedded tissue samples of pancreatic adenocarcinoma, 20 samples of chronic pancreatitis, and 8 samples of normal pancreas were obtained. We investigated the association of miR-203 expression measured by quantitative reverse-transcription polymerase chain reaction assays with clinicopathological parameters and survival times.miR-203 was overexpressed in pancreatic adenocarcinoma samples compared with chronic pancreatitis (P < 0.001) and normal pancreas (P = 0.001) samples. An association between miR-203 expression and clinicopathological factors of pancreatic adenocarcinoma was not observed. On univariate analysis, the high-miR-203 group and the subgroup (20%) of cases with the highest miR-203 overexpression had significantly shorter survival time (P = 0.048 and P = 0.024, respectively). Multivariate analysis revealed that miR-203 expression was an independent predictor of poor prognosis in cases with no residual tumor (relative risk 2.298, P = 0.027).miR-203 expression is a new prognostic marker in pancreatic adenocarcinoma patients.